Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma. Kurashina R, Ando K, Inoue M, Izumi K, et al. Anticancer Res 2022;42:1131-1136.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kurashina R, Ando K, Inoue M, Izumi K, et al. Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma. Anticancer Res 2022;42:1131-1136.
PMID: 35093916